Q&A: How studying two different viruses can lead to new strategies for more potent antiviral treatments

Beyond both being viruses, HIV-1 and SARS-CoV-2 don't seem to have a lot in common. HIV-1 is a retrovirus that integrates ...
Seeking Alpha

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Forbes

How A New Covid-19 Antibody Could Contribute To Advanced Vaccine Development

In the ongoing Omicron era, a new Covid-19 antibody could renew optimism for urgently required SARS-CoV-2 monoclonal therapies. Over the last three years, various ...
The New England Journal of Medicine

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

In this ongoing, randomized, phase 3 trial, sotrovimab (a SARS-CoV-2–targeted monoclonal antibody) or placebo was administered to outpatients within 5 days after the onset of Covid-19 symptoms. The ...
Tahoe Daily Tribune.com

SARS deserves better treatment than AIDS

From Wednesday to Thursday the World Health Organization reported an additional 47 cases and one death from Severe Acute Respiratory Syndrome. This brings the total to 2,270 cases and 79 deaths in 16 ...
National Academies of Sciences%2c Engineering%2c and Medicine

Long-Term Health Effects of COVID-19: Disability and Function Following SARS-CoV-2 Infection

The Social Security Administration (SSA) provides disability benefits to people living with disabilities through two programs: Social Security Disability Insurance (SSDI) and Supplemental Security ...
Seeking Alpha

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...